The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inhibitors (AstraZeneca / Merck Sharp & Dohme’s Lynparza, Clovis Oncology’s Rubraca, and GlaxoSmithKline / Tesaro’s Zejula), treatment is moving toward a targeted approach. Multiple combination therapies incorporating immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the treatment of this disease.

Questions Answered:

  • What is the size of the drug-treatable ovarian cancer population, and how will the drug-treatment rates change over time?
  • What is the current state of treatment in ovarian cancer? Which drugs are the most important? What are interviewed experts’ insights on current treatment options? What are the main unmet needs in the treatment of ovarian cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer market? What notable therapies are progressing in early-phase trials?
  • What is the expected impact of the approvals of Roche / Genentech /Chugai’s Tecentriq, GlaxoSmithKline / Tesaro’s dostarlimab, AstraZeneca’s Imfinzi, Bristol Myers Squibb / Ono Pharmaceutical’s Opdivo, and Merck Sharp & Dohme’s Keytruda on the ovarian cancer market? What competition will other drug classes present to immune checkpoint inhibitors?
  • What are the drivers and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: More than 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.

Key companies: Roche / Genentech, GlaxoSmithKline / Tesaro, Clovis Oncology, AstraZeneca, AbbVie, Merck KGaA, Pfizer, Bristol Myers Squibb, Merck & Co., ImmunoGen, Sotio, VBL Therapeutics, Novartis.

Key drugs: Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib), Talzenna (talazoparib), Opdivo (nivolumab), Bavencio (avelumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), Keytruda (pembrolizumab), Mekinist (trametinib), dostarlimab, mirvetuximab soravtansine, cediranib, ofranergene obadenovec, DCVAC/OvCa, mirvetuximab soravtansine, oregovomab.

Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).

Population segments in market forecast: Early-stage first line, advanced-stage first line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth and subsequent lines.

Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2029, segmented by brands/generics and epidemiological subpopulations.

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Key Updates
          • January 2021
          • October 2020
          • August 2020
          • April 2020
          • March 2020
        • Market Outlook
          • Key Findings
            • Market Share of Ovarian Cancer Drug Classes: 2019
            • Market Share of Ovarian Cancer Drug Classes: 2029
            • Drug-Treatable Population Share and Major-Market Sales Share in Ovarian Cancer: 2019
            • Drug-Treatable Population Share and Major-Market Sales Share in Ovarian Cancer: 2029
            • Population Positioning of Therapies in Ovarian Cancer: United States
            • Population Positioning of Therapies in Ovarian Cancer: Europe
            • Population Positioning of Therapies in Ovarian Cancer: Japan
            • Ovarian Cancer SWOT Analysis
          • COVID-19: Areas of Potential Forecast Impact
            • Market Drivers and Constraints
              • What Factors Are Driving the Market for Ovarian Cancer?
              • What Factors Are Constraining the Market for Ovarian Cancer?
              • Major-Market Sales for Ovarian Cancer by Region: 2019-2029
              • Major-Market Sales for Ovarian Cancer by Drug Class: 2019-2029
              • Major-Market Sales of Targeted Therapies in the Ovarian Cancer Market: 2019-2029
              • Patient Share of PARP Inhibitors by Patient Population in the United States: 2019-2029
            • Segment-Specific Trends
              • Patient-Share Dynamics of Key Therapies (Excluding Maintenance) in First-Line Advanced-Stage Ovarian Cancer in the United States: 2019-2029
              • Patient-Share Dynamics of Maintenance Therapies in First-Line Advanced-Stage Ovarian Cancer in the United States: 2019-2029
              • Patient-Share Dynamics of Key Therapies Excluding Maintenance Treatments in the Second-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2019-2029
              • Patient-Share Dynamics of Maintenance Therapies in the Second-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2019-2029
              • Patient-Share Dynamics of Key Therapies Excluding Maintenance Treatments in the Third-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2019-2029
              • Patient-Share Dynamics of Maintenance Therapies in the Third-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2019-2029
              • Patient-Share Dynamics of Second-Line Platinum-Resistant and Platinum-Refractory Ovarian Cancer in the United States: 2019-2029
              • Patient-Share Dynamics of Third-Line Platinum-Resistant and Platinum-Refractory Ovarian Cancer Setting in the United States: 2019-2029
              • Patient-Share Dynamics of Key Therapies in the Fourth- and Subsequent-Line Ovarian Cancer Setting in the United States: 2019-2029
          • Forecast
            • Market Forecast Assumptions
          • Etiology and Pathophysiology
            • Disease Overview
              • Disease Pathophysiology
                • Disease Pathogenesis
                • Disease Classification
                • Ovarian Cancer Histologies
                • Molecular Subtypes and Key Pathways
                • Screening Tests: CA-125
              • Staging and Classification
                • Staging and Grading
                • International Federation of Gynecology and Obstetrics Staging System for Cancer of the Ovary, Fallopian Tube, and Peritoneum
                • Stage I-II
                • Stage III-IV
              • Key Pathways and Drug Targets
                • Key Pathways and Drug Targets for Ovarian Cancer
                • Key Signaling Pathways in Epithelial Cells
                • PARP Inhibition: Mechanism of Action
                • Folate Receptor Pathway
                • Immune Checkpoint Inhibitors and Modulators
            • Epidemiology
              • Key Findings
                • Epidemiology Populations
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Incidence of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
                  • Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: 2019-2029
                  • Contributing Proportion of Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers in 2019
                  • Disease Definition
                  • Methods
                  • Sources Used for Stage at Diagnosis of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
                  • Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer by Stage: 2019-2029
                  • Stage Distribution of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in the Major Mature Markets in 2019
                  • Disease Definition
                  • Methods
                  • Sources Used for BRCA Mutations in Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
                  • Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer by BRCA Mutation: 2019-2029
                  • Disease Definition
                  • Methods
                  • Sources Used for Recurrent Incidence of Epithelial Ovarian and Fallopian Tube Cancer
                  • Recurrent Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: 2019-2029
                  • Ovarian Cancer Patient Flow
                  • Drug-Treatable Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: 2019-2029
                  • Drug-Treated Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: 2019-2029
              • Current Treatment
                • Key Findings
                  • Treatment Goals
                    • Key Endpoints Used in Clinical Trials for Ovarian Cancer
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes
                    • Current Treatments Used for Ovarian Cancer
                    • Market Events Impacting the Use of Key Current Therapies in Ovarian Cancer
                    • Advantages and Disadvantages of Bevacizumab
                    • Key Results from Clinical Trials Investigating Bevacizumab for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development
                    • Key Ongoing Clinical Trials of Bevacizumab in the Treatment of Ovarian Cancer
                    • Expert Insight: Bevacizumab
                    • Advantages and Disadvantages of Lynparza
                    • Key Results from Clinical Trials Investigating Lynparza for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development
                    • Key Ongoing Clinical Trials of Lynparza in the Treatment of Ovarian Cancer
                    • Expert Insight: Lynparza
                    • Advantages and Disadvantages of Rubraca
                    • Key Results from Clinical Trials Investigating Rubraca for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development
                    • Key Ongoing Clinical Trials Investigating Rubraca in the Treatment of Ovarian Cancer
                    • Expert Insight: Rubraca
                    • Advantages and Disadvantages of Zejula
                    • Key Results from Clinical Trials Investigating Zejula for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development
                    • Expert Insight: Zejula
                    • Key Results from Clinical Trials Investigating Yondelis for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development
                  • Medical Practice
                    • Early-Stage First-Line Ovarian Cancer
                    • Advanced-Stage First-Line Ovarian Cancer
                    • Second- and Third-Line Platinum-Sensitive Ovarian Cancer
                    • Second- and Third-Line Platinum-Resistant and -Refractory Ovarian Cancer
                    • Fourth- and Subsequent-Line Ovarian Cancer
                    • Country-Specific Ovarian Cancer Treatment Guidelines
                    • Patient Characteristics Influencing Drug Selection in Ovarian Cancer
                    • Treatment Decision Tree for Early- and Advanced-Stage Ovarian Cancer: United States
                    • Treatment Decision Tree for Early- and Advanced-Stage Ovarian Cancer: Europe
                    • Treatment Decision Tree for Early- and Advanced-Stage Ovarian Cancer: Japan
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in Ovarian Cancer
                  • Top Unmet Needs in Ovarian Cancer: Current and Future Attainment
                • Emerging Therapies
                  • Key Findings
                    • Pipeline Trends for Ovarian Cancer
                  • Key Emerging Therapies
                    • Therapies in Late-Phase Development for Ovarian Cancer
                    • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Veliparib for the Treatment of Ovarian Cancer
                    • Veliparib Clinical Development
                    • Expert Insight: Veliparib
                    • Expectations for Launch and Sales Opportunity of Veliparib in Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Ovarian Cancer
                    • Tecentriq Clinical Development
                    • Expert Insight: Tecentriq
                    • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials of Opdivo in the Treatment of Ovarian Cancer
                    • Opdivo Clinical Development
                    • Expert Insight: Opdivo
                    • Expectations for Market Authorization and Sales Opportunity of Opdivo in Ovarian Cancer
                    • Key Results from Clinical Trials Investigating Keytruda for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials of Keytruda in the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Keytruda
                    • Expert Insight: Keytruda
                    • Expectations for Market Authorization and Sales Opportunity of Keytruda in Ovarian Cancer
                    • Key Results from Clinical Trials Investigating Imfinzi for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Imfinzi
                    • Expert Insight: Imfinzi
                    • Expectations for Launch and Sales Opportunity of Imfinzi in Ovarian Cancer
                    • Key Ongoing Clinical Trials of Dostarlimab in the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Dostarlimab
                    • Expert Insight: Dostarlimab
                    • Expectations for Launch and Sales Opportunity of Dostarlimab in Ovarian Cancer
                    • Key Results from Clinical Trials Investigating DCVAC/OvCa for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials Investigating DCVAC/OvCa in the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of DCVAC/OvCa
                    • Expectations for Market Authorization and Sales Opportunity of DCVAC/OvCa in Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Mirvetuximab Soravtansine for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Mirvetuximab Soravtansine
                    • Key Ongoing Clinical Trials of Mirvetuximab Soravtansine in the Treatment of Ovarian Cancer
                    • Expert Insight: Mirvetuximab Soravtansine
                    • Expectations for Launch and Sales Opportunity of Mirvetuximab Soravtansine in Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Cediranib for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials of Cediranib for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Cediranib
                    • Expert Insight: Cediranib
                    • Expectations for Launch and Sales Opportunity of Cediranib in Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Ofranergene Obadenovec for the Treatment of Ovarian Cancer
                    • Key Ongoing Clinical Trials of Ofranergene Obadenovec in the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Ofranergene Obadenovec
                    • Expert Insight: Ofranergene Obadenovec
                    • Expectations for Launch and Sales Opportunity of Ofranergene Obadenovec in Ovarian Cancer
                    • Key Results from Select Clinical Trials Investigating Mekinist for the Treatment of Ovarian Cancer
                    • Ongoing Clinical Development of Mekinist
                    • Expert Insight: Mekinist
                    • Expectations for Launch and Sales Opportunity of Mekinist in Ovarian Cancer
                    • Oregovomab
                    • Ongoing Clinical Development of Oregovomab
                    • Key Results from Select Clinical Trials Investigating Oregovomab in Ovarian Cancer
                    • Key Ongoing Clinical Trials of Oregovomab for the Treatment of Ovarian Cancer
                    • Expert Insight: Oregovomab
                    • Expectation for Market Authorization of Oregovomab
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Phase I/II Development for Ovarian Cancer
                • Access and Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in Ovarian Cancer: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in Ovarian Cancer: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in Ovarian Cancer: Japan
                    • General Reimbursement Environment: Japan
                • Appendix
                  • Key Abbreviations Related to Ovarian Cancer
                  • Brands, Marketers, and Generic Availability of Current Therapies Used for Ovarian Cancer by Market
                  • Ovarian Cancer Bibliography

              Author(s): Grace Mitchell, M.Res.; Alexandre Vo Dupuy, Pharm.D., M.Sc.

              Grace Mitchell, M.Res., is an analyst on the Oncology team at DRG, part of Clarivate. She has authored content on immune checkpoint inhibitors, bladder cancer, and ovarian cancer. She obtained her master’s degree in cancer sciences, with a focus on the expression of immune checkpoints in diffuse large B-cell lymphoma, from the University of Birmingham. She also holds an Honor’s degree in biomedical science from the University of Reading.

              Alexandre Vo Dupuy, M.Sc., Pharm.D., is a senior epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux.


              Related Reports

              Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)

              The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncolo...

              View Details

              Ovarian Cancer - Epidemiology - Mature Markets

              DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We...

              View Details